As with all research peptides, the goal is to build a data set that can either justify more formal studies or reveal that the compound is not suitable for future development
As the systematic review noted: No clinical safety data were found. When the FDA says insufficient evidence, they mean itwe literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road
Growth hormone-releasing peptides and their effects on bone mineral density
doi:10.1080/09513590.2019.1576620
BPC-157 has become a recognised laboratory research peptide within this field, appearing in studies investigating cellular signalling, tissue biology and the molecular mechanisms involved in physiological repair processes
A common starting strategy for patients with sensitive systems is to begin with 250 mg to 500 mg in the morning, gradually increasing the dose and adding a second midday administration as tolerated